Related Experiment Video
Updated: Oct 13, 2026

Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies
Published on: January 16, 2019
Abstract:
Described are primary treatment protocols for 1) those patients with gorssly unresectable stage III or IV ovarian carcinoma, considered reasonable candidates for therapeutic trials aimed at the identification of antitumor activity as determined by the regression of objectively evaluable lesions; and 2) those patients with stage II or III ovarian carcinoma, with little or no visible tumor remaining after surgery, considered reasonable candidates for therapeutic trials involving regimens that may delay or prevent the recurrence of clinically apparent disease. Both protocol involve initially a comparison of cyclophosphamide alone with cyclophosphamide plus adriamycin. A third protocol--an activity-seeking study of two new cytotoxic agents, developed to provide secondary treatment opportunities for patients who have failed on one of the primary chemotherapy protocols--is designed to seek evidence of any cross-resistance between cytembena (beta-4-methoxybenzoyl beta-cis-bromacrylate) and VP-16 (4'-demethyl-epipodophyllotoxin-beta-D-ethylidene glucoside). Data from all three protocols are so far insufficient to allow meaningful analysis of their results.
Insights
This study evaluates chemotherapy protocols for ovarian carcinoma, comparing cyclophosphamide alone versus cyclophosphamide with adriamycin. Further research is needed as current data is insufficient for analysis.
Area of Science:
- Oncology
- Medical Oncology
- Clinical Trials
Background:
- Ovarian carcinoma presents significant treatment challenges, particularly in advanced stages (III-IV) and post-surgically (II-III).
- Effective therapeutic strategies are needed to improve outcomes for patients with unresectable or recurrent ovarian cancer.
Purpose of the Study:
- To describe primary treatment protocols for advanced and post-surgical ovarian carcinoma.
- To evaluate the efficacy of cyclophosphamide-based chemotherapy regimens.
- To investigate novel cytotoxic agents for secondary treatment and assess cross-resistance.
Main Methods:
- Two primary protocols were designed: one for unresectable stage III-IV ovarian cancer and another for minimal residual disease in stage II-III.
- Both primary protocols involve comparing cyclophosphamide monotherapy with a combination of cyclophosphamide and adriamycin.
- A third protocol was established to evaluate two new cytotoxic agents, cytembena and VP-16, for secondary treatment and cross-resistance studies.
Main Results:
- Current data from all three protocols are insufficient for meaningful analysis.
- Preliminary data collection is ongoing for the cyclophosphamide and adriamycin comparisons.
- Activity-seeking data for cytembena and VP-16 are also pending.
Conclusions:
- The described protocols aim to identify effective treatments for ovarian carcinoma at various stages.
- Further data collection and analysis are required to determine the efficacy of the investigated chemotherapy regimens.
- The study highlights the ongoing search for improved therapeutic options and understanding drug resistance in ovarian cancer.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Longitudinal Studies